Full-Time

AI and Data Scientist

Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharma maker of Abilify

Compensation Overview

$150k - $224.3k/yr

+ Incentive opportunity

Princeton, NJ, USA

In Person

Master's, PhD

Category
Data & Analytics (1)
Required Skills
LLM
Python
Data Science
R
Product Management
SQL
Machine Learning
Data Engineering
RAG
Data Governance
HIPAA
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • Deep expertise and hands-on experience in the foundations of artificial intelligence and machine learning in an industry setting.
  • Understanding of artificial intelligence and machine learning technologies.
  • A strong grasp of pharmaceutical research and development processes, drug development, research and development data, enterprise data, and data lifecycle management.
  • Deep technical proficiency in artificial intelligence and data science.
  • Proven product management expertise.
  • Experience architecting, developing, and maintaining scalable artificial intelligence and generative artificial intelligence solutions.
  • Knowledge of responsible and ethical artificial intelligence use, regulatory compliance, governance policies, and auditability and traceability.
  • Knowledge of research and development data, including clinical trial, textual, clinical, and safety data.
  • Knowledge of pharmaceutical industry regulations, including HIPAA and GxP.
  • Ability to translate complex artificial intelligence concepts for non-technical stakeholders.
  • Ability to guide cross-functional teams of data scientists and engineers and oversee developers and vendor resources.
  • Ability to identify stakeholder processes and artificial intelligence needs and convert them into a prioritized artificial intelligence portfolio.
  • Ability to design scalable, secure enterprise data science and artificial intelligence solutions aligned with enterprise architecture, compliance needs, and organizational priorities.
  • Ability to identify and resolve potential artificial intelligence system issues during development and production support.
  • Ability to develop reusable data and artificial intelligence components and apply scalable data and artificial intelligence engineering approaches.
  • Ability to collaborate with data and artificial intelligence engineers, artificial intelligence scientists, information technology professionals, and cloud architects.
  • Ability to communicate strategy, progress, and outcomes to technical teams and executive leadership.
Responsibilities
  • Develop, implement, and deliver artificial intelligence, machine learning, and generative artificial intelligence applications that provide insights, support decisions, and improve operational efficiency across research and development functions.
  • Create product vision, set the roadmap, and manage the end-to-end artificial intelligence product lifecycle while ensuring regulatory compliance.
  • Provide technical expertise on responsible and ethical artificial intelligence use, and develop best practices, standards, and documentation for responsible artificial intelligence solutions, including retrieval-augmented generation and agentic architectures.
  • Provide technical input on the artificial intelligence ecosystem and architecture, including platform evolution and new capability development.
  • Guide developers and extended team members or vendor resources, providing oversight on architecture, solutions, artificial intelligence and machine learning model development, testing, and validation.
  • Collaborate with stakeholders to understand processes and artificial intelligence needs and convert them into a prioritized artificial intelligence portfolio.
  • Design and oversee enterprise data science and artificial intelligence solutions for analytics, artificial intelligence, and generative artificial intelligence, ensuring scalable and secure structures.
  • Identify and resolve potential artificial intelligence system issues during development and production support of data analytics and artificial intelligence applications.
  • Develop reusable data and artificial intelligence components and promote their use across the data and artificial intelligence ecosystem and business functions.
  • Use research and development data to develop pragmatic operational artificial intelligence use cases, including analytics, traditional artificial intelligence and machine learning, and generative artificial intelligence.
  • Participate in design and architecture reviews for data science and artificial intelligence solutions.
  • Collaborate with internal data and artificial intelligence engineers, artificial intelligence scientists, information technology professionals, and cloud architects to align infrastructure and technical solutions with enterprise architecture, compliance needs, and organizational priorities.
  • Lead the industrialization of artificial intelligence, generative artificial intelligence, and data science applications from prototypes and proofs of concept to production systems.
  • Develop and implement scalable engineering solutions, data repositories, data representations, and knowledge engineering to support data and artificial intelligence strategy execution and enable model training, validation, and deployment.
  • Collaborate with data scientists and artificial intelligence and machine learning scientists to build engineering frameworks for retrieval-augmented generation, agentic architectures, and other generative artificial intelligence workflows in research and development.
  • Introduce new artificial intelligence, machine learning, and generative artificial intelligence technologies into existing drug development processes to identify opportunities for innovation and automation.
  • Ensure that data and artificial intelligence solutions comply with pharmaceutical industry regulations, including HIPAA, GxP, and other relevant standards.
  • Drive organizational awareness of artificial intelligence and machine learning applications and the importance of a strong data and artificial intelligence engineering foundation.
  • Provide artificial intelligence support for data and information governance, quality, and FAIR data.
  • Foster a culture of innovation, continuous learning, and accountability within and across the team.
  • Collaborate with Legal and Compliance teams to embed auditability and traceability into artificial intelligence and generative artificial intelligence workflows.
  • Serve as an artificial intelligence and data engineering expert for internal portfolio and organization-wide initiatives, reviews, and artificial intelligence committees.
  • Build trusted relationships with stakeholders across research and development, scientific and operations artificial intelligence and data science teams, information technology, and external partners.
  • Partner with research and development teams to translate complex scientific challenges into clear, executable data and artificial intelligence projects.
Desired Qualifications
  • A master's degree in Data Science, Computer Engineering, Computer Science, Physics, Statistics, Information Systems, or a related discipline with a focus on advanced and modern data science, including the use of artificial intelligence and machine learning; a PhD is preferred.
  • Experience in software or product engineering.
  • Experience with data science-enabling technology such as Dataiku Data Science Studio, AWS SageMaker, or other data science platforms.
  • Strong proficiency in SQL and programming languages such as Python or R.
  • Experience architecting, building, and maintaining large-scale data and artificial intelligence solutions in a scientific, regulated, or research-heavy environment.
  • Strong experience within the pharmaceutical, biotech, or life sciences industry, particularly within research and development.
  • A proven track record of implementing and deploying generative artificial intelligence and large language model applications in production environments.
  • Expertise in real-world data assets and using them to generate scientific evidence and guide operational effectiveness and efficiencies.
  • Deep expertise across data engineering, data representation, generative artificial intelligence, artificial intelligence, and machine learning techniques, with experience architecting and delivering artificial intelligence and machine learning use cases.
  • Strong internal and cross-functional collaboration and project management skills focused on delivering impactful initiatives.
Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Otsuka closed Transcend in June 2026, expanding psychiatry beyond Abilify dependence.
  • DAWNZERA gained EU authorization in January 2026, opening paid sales across 27 countries.
  • Paradise uRDN and CART BP pro broaden Japan's hypertension platform and device distribution.

What critics are saying

  • SIMTRIYO waits on DEA scheduling, delaying revenue until late 2026.
  • VOYXACT's accelerated approval depends on confirmatory kidney-outcome data; failure risks withdrawal.
  • Transcend's TSND-201 PTSD program remains clinical-stage, risking a $1.225 billion write-down.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs CNS, nephrology, and device assets across Japan, US, and Europe.
  • SIMTRIYO gives Otsuka a first-in-class ADHD stimulant franchise after July 2026 FDA approval.
  • DAWNZERA and VOYXACT anchor rare-disease pipelines with global reimbursement and accelerated paths.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.